VERU INC. VERU
We are a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of cardiometabolic and inflammatory diseases. Our drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator ("SARM"), is being developed as a next generation drug that makes weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass. This activity leads to improved body composition and physical function with expected clinically meaningful incremental weight reduction versus GLP-1 RA monotherapy. Sabizabulin, a microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease. On December 30, 2024, the Company sold its FDA-approved commercial product, the FC2 Female Condom® (Internal Condom), for the dual protection against unplanned pregnancy and sexually transmitted infections (the "FC2 Business").
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $16.9M | $16.3M | $39.4M | $61.3M | $42.6M | $31.8M | $15.9M | $13.7M | $22.1M |
| Cost of revenue | — | $11.0M | $8.7M | $8.8M | $13.3M | $11.8M | $10.1M | $7.1M | $6.6M | $8.8M |
| Gross profit | — | $5.9M | $7.6M | $30.6M | $47.9M | $30.8M | $21.7M | $8.8M | $7.0M | $13.3M |
| R&D | $15.6M | $12.8M | $51.2M | $70.9M | $32.7M | $16.9M | $13.7M | $10.9M | $3.1M | $99.4K |
| SG&A | $19.9M | $24.6M | $48.1M | $43.2M | $20.7M | $14.5M | $14.3M | $14.8M | $11.5M | $8.7M |
| Total operating expenses | $35.5M | $37.4M | $107.1M | $114.1M | $53.4M | $31.4M | $28.1M | $29.6M | $15.5M | $10.3M |
| Operating income | -$24.8M | -$36.2M | -$93.8M | -$83.5M | $13.0M | -$14.7M | -$6.4M | -$20.9M | -$8.5M | $3.0M |
| Interest expense | — | $607.5K | $2.4M | $4.4M | $4.9M | $4.6M | $4.7M | $3.0M | — | — |
| Pre-tax income | -$22.7M | -$37.8M | -$92.7M | -$83.8M | $4.3M | -$20.1M | -$12.3M | -$23.1M | -$8.6M | $2.8M |
| Income tax | $0 | $0 | $480.2K | $236.4K | $3.1M | $1.1M | $303.9K | $866.1K | $2.0M | $2.5M |
| Net income | -$22.7M | -$37.8M | -$93.2M | -$84.0M | $7.4M | -$19.0M | -$12.0M | -$23.9M | -$6.6M | $344.7K |
| EPS, basic | -1.55 | -2.80 | -1.10 | -1.05 | 0.10 | -0.28 | — | — | -0.25 | 0.01 |
| EPS, diluted | — | — | -1.10 | -1.05 | 0.09 | -0.28 | -0.19 | -0.44 | -0.25 | 0.01 |
| Shares, diluted (wtd. avg.) | $14.6M | $13.5M | $85.0M | $80.1M | $83.8M | $66.8M | — | — | $34.6M | $28.9M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $15.8M | $24.9M | $9.6M | — | — | — | — | — | — | — |
| Receivables | — | $4.0M | $4.5M | $3.6M | $8.8M | $5.2M | $5.0M | $4.0M | $3.4M | $10.8M |
| Inventory | — | $4.1M | $6.7M | $8.6M | $5.6M | $6.7M | $3.6M | $2.3M | $2.8M | $2.5M |
| Total current assets | $18.9M | $35.2M | $22.9M | $104.0M | $151.8M | $27.0M | $16.8M | $11.2M | $10.3M | $16.3M |
| Property, plant and equipment | $364.8K | $481.4K | $1.7M | $1.2M | $592.6K | $312.7K | $351.9K | $404.6K | $555.5K | $825.1K |
| Goodwill | $6.9M | $6.9M | $6.9M | $6.9M | $6.9M | $6.9M | $6.9M | $6.9M | $6.9M | — |
| Other intangibles | — | $0 | $6.0K | $4.0M | $4.0M | $5.8M | $20.2M | $20.5M | $20.8M | — |
| Total assets | $29.8M | $60.4M | $50.0M | $135.4M | $178.1M | $51.5M | $53.6M | $48.5M | $55.3M | $38.6M |
| Accounts payable | $3.1M | $2.3M | $12.9M | $22.0M | $3.4M | $2.8M | $3.1M | $3.2M | $2.7M | $701.0K |
| Total current liabilities | $7.8M | $11.9M | $17.8M | $38.7M | $15.8M | $14.7M | $14.0M | $13.6M | $5.5M | $3.3M |
| Long-term debt | — | — | — | — | — | — | — | $1.8M | — | — |
| Total liabilities | $11.5M | $28.1M | $30.3M | $52.6M | $25.9M | $21.4M | $21.3M | $19.0M | $6.9M | $4.7M |
| Retained earnings | -$317.3M | -$294.6M | -$256.8M | -$163.6M | -$81.8M | -$89.2M | -$70.2M | -$58.2M | -$34.3M | -$27.7M |
| Total equity | $18.3M | $32.3M | $19.7M | $82.8M | $154.5M | $30.1M | $32.3M | $29.5M | $48.5M | $33.9M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$30.0M | -$21.7M | -$88.0M | -$47.5M | -$15.6M | -$1.9M | -$5.5M | -$11.5M | $982.9K | -$1.7M |
| Depreciation and amortisation | $152.1K | $268.2K | $269.9K | $138.0K | $98.0K | $146.0K | — | $176.8K | $334.0K | $422.9K |
| Stock-based compensation | $8.1M | $13.6M | $17.9M | $11.2M | $5.1M | $2.6M | $1.9M | $1.6M | $756.3K | $499.9K |
| Capital expenditure | $1.1K | $158.3K | $665.7K | $733.1K | $376.6K | $105.8K | $108.5K | $50.7K | $133.5K | $6.4K |
| Investing cash flow | $25.1M | $146.2K | $6.3M | $4.3M | $14.6M | -$105.8K | -$108.5K | -$50.7K | -$90.4K | -$6.4K |
| Financing cash flow | -$4.2M | $36.8M | $11.1M | $1.1M | $109.7M | $9.3M | $8.1M | $12.1M | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001437749-25-038089.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |